Article info

Download PDFPDF
The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines

Authors

  1. Correspondence to Dr Zhang Zhang, Department of Pathology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; zhangzhang714{at}163.com
View Full Text

Citation

Yang L, Chen M, Pu T, et al
The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines

Publication history

  • Received September 18, 2019
  • Revised October 21, 2019
  • Accepted October 22, 2019
  • First published November 15, 2019.
Online issue publication 
April 20, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.